Ethics of giving antipsychotic medication to at-risk young people

@article{Jorm2012EthicsOG,
  title={Ethics of giving antipsychotic medication to at-risk young people},
  author={Anthony F. Jorm},
  journal={Australian \& New Zealand Journal of Psychiatry},
  year={2012},
  volume={46},
  pages={908 - 909}
}
  • A. Jorm
  • Published 16 July 2012
  • Psychology, Medicine
  • Australian & New Zealand Journal of Psychiatry
In his response to critics of early intervention for psychosis, Patrick McGorry (2012) makes some negative statements about those who have questioned the ethics of using antipsychotic medication with young people at risk of psychosis. He charges that these critics ‘have recently sought to censor such research through coordinated pressure exerted through mainstream and social media, through frivolous freedom of information requests which consume the time and energy of researchers in universities… 
Ethical Challenges in the Primary Prevention of Schizophrenia.
TLDR
A set of questions is suggested that may assist investigators, funders, and IRBs to assess the ethical acceptability of studies aimed at primary prevention of schizophrenia, so as best to protect subjects.
Treatment to reduce risk of psychosis: The need to consider the potential harms as well as the benefits
  • Anthony F Jorm
  • Psychology, Medicine
    The Australian and New Zealand journal of psychiatry
  • 2013
TLDR
Preventing a first episode of psychosis: Meta-analysis of randomized controlled prevention trials and a heuristic framework for choosing earlier, safer and more effective interventions.
What constitutes ‘good practice’ in early intervention for psychosis? Analysis of clinical guidelines
TLDR
It is suggested that the procedural and substantive factors highlighted in this paper contribute useful dimensions for the eventual evaluation of good practice in EIP services across England.
The prodromal psychosis debate
  • S. Rosenman
  • Psychology, Medicine
    The Australian and New Zealand journal of psychiatry
  • 2013
TLDR
There may be significant disagreement with clinical diagnoses and suggests that clinical relevance and clinical judgments about key cognitive and motivational drivers that underlie symptoms are impor­ tant considerations, consistent with research advocating that the gold standard of diagnosis may be the ‘LEAD’ standard.

References

SHOWING 1-10 OF 13 REFERENCES
Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers
TLDR
An association between hypodopaminergic states and depressive symptoms was observed which may be amplified by a genetic predisposition and induced substantial impairments in several domains of subjective well-being.
Truth and reality in early intervention
  • P. McGorry
  • Medicine, Psychology
    The Australian and New Zealand journal of psychiatry
  • 2012
‘I have seen how much progress early intervention teams have made, how innovative they have been, and the impact they are having. I now believe that early intervention will be the most important and
Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis.
TLDR
Two key hypotheses were identified: in general, there is no difference in cardiovascular risk assessed by weight or metabolic indices between individuals with an untreated first episode of psychosis and healthy controls and cardiovascular risk increases after first exposure to any antipsychotic drug.
Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia.
TLDR
It is suggested that antipsychotics have a subtle but measurable influence on brain tissue loss over time, suggesting the importance of careful risk-benefit review of dosage and duration of treatment as well as their off-label use.
Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
TLDR
Single doses of both haloperidol and risperidone produce negative symptoms in normal individuals and drowsiness may be an important confounding factor in the assessment of negative Symptoms in antipsychotic trials.
Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam.
  • K. Anderson, J. Shneerson
  • Medicine, Psychology
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
  • 2009
TLDR
Several novel and effective therapies are reported in a series of patients under long-term follow-up for RBD, in particular zopiclone, which can be as effective and may be better tolerated as clonazepam.
The Influence of Chronic Exposure to Antipsychotic Medications on Brain Size before and after Tissue Fixation: A Comparison of Haloperidol and Olanzapine in Macaque Monkeys
TLDR
Chronic exposure of non-human primates to antipsychotics was associated with reduced brain volume and a pronounced general shrinkage effect of ∼20% and a highly significant variation in shrinkage across brain regions.
Prevalence and correlates of frequent nightmares: a community-based 2-phase study.
TLDR
Frequent nightmares were not uncommon in the general population and were associated with a constellation of factors, including sociodemographic characteristics and comorbid sleep and psychiatric disorders, irrespective of psychiatric diagnosis.
Nightmares in crisis: clinical applications of lucid dreaming techniques.
  • A. Brylowski
  • Psychology, Medicine
    Psychiatric journal of the University of Ottawa : Revue de psychiatrie de l'Universite d'Ottawa
  • 1990
TLDR
A patient in crisis was offered treatment with a major focus on alleviating nightmares using lucid dreaming, and the techniques appeared to play a role in the reduction of nightmare frequency, intensity, and distress.
Drug induced nightmares—an etiology based review
TLDR
The objective is to provide a clinical and theoretical framework useful in categorizing the potential and reported drug effects on nightmares, which could alter dreaming and nightmares.
...
...